transformation towards global business services in …...global business services - for finance...
Post on 18-Jun-2020
0 Views
Preview:
TRANSCRIPT
Transformation towards Global Business Services in Finance
November 27, 2013
Round Table – Brussels
UCB: reinventing itself, leveraging a solid heritage to deliver sustainable and superior value for patients
1928: Emmanuel Janssen establishes
UCB in Brussels
1972: A new state-of-the-art R&D center in Braine-l’Alleud,
Belgium
1980s: UCB registers its novel
antihistamine Zyrtec®
1990s: approval of Keppra®, a novel
anti-epileptic
2004: UCB acquires British
biotech company Celltech
2006: UCB acquires German pharma company Schwarz Pharma
Today Combine leadership in antibody research
& chemistry expertise to better
treat severe diseases
1928 1952 1972 1980s 1990s 2004 2006 2008-2012 Today
Chemical Group Primary Care Pharma Specialty Bio-Pharma
Focus: CNS + immunology
Launch of Cimzia®, Vimpat® & Neupro®
(CVN)
1952: UCB discovers Atarax®
U.S. license awarded to Pfizer
1936: UCB enters the United States
1936
2
Our Strategies 3
UCB’s priorities 2013 and beyond…
• Building on the growth momentum of the company’s core medicines Cimzia®, Vimpat® and Neupro®
• Growing revenues in Emerging Markets • Advancing UCB’s rich pipeline towards approval • Delivering breakthrough discovery • Improving our profitability to peer level
Growth prospects confirmed with 5 main drivers 5
Mature product portfolio
Emerging markets
Cimzia®, Vimpat®, Neupro®
Supe
rior a
nd s
usta
inab
le v
alue
R&D investment per employee, in top EU companies (EU scoreboard 2013) mployees, in top EU companies
Top 50 EU companies by R&D/Employees, the 2013 industrial R&D investment scoreboard
European Commission, Dec 2013
R&
D p
er e
mpl
oyee
s (E
UR
)
6
0.000
10.000
20.000
30.000
40.000
50.000
60.000
70.000
80.000
90.000
2.8 2.6
2.2 2.1 1.9
1.6 1.5 1.4
1.2 1.2 1.1 1.1 1.0
0.7 0.5
#1 UCB #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 #14 #15
Number of New Molecular Entities (NMEs) per $bn1
UCB’s pipeline: one of the most productive in the industry
7
Keeping our competitive edge is key
1 Phase 3 NMEs / 2013 R&D Source: UCB company information
Poland Romania
India China
2009
2011
2013
• 31 countries, 12 languages • Multiple ERPs • Payables, Accounting,
Procurement • 50% decoupled model • 88 FTEs
• Transitions in parallel with SAP implementation
• 2 new delivery centers in China & Poland
• Deployed Smart Enterprise Processes diagnostics
• Process automation
• Global Business Services design & implementation
• New Org with an end-to-end process ownership
• Procurement Hub implementation • Transitions of high end work • 200+ FTEs
Transforming UCB Finance function globally
Reducing cost through offshoring
Transforming processes through standardization
Generating value through Finance Transformation
Global Business Services: what are we after
User satisfaction: make selected global processes effective, listening to UCB-voices
Cost reduction and possibilities to reallocate resources, focus on Core
Process effectiveness and Compliance
Satisfied customers, served by compliant and efficient global processes
9
Global Business Services - for Finance transactional activities -
GBS Lead
S2P Value Stream
Partnerships & perf. Mgnt
R2R Value Stream Lead
Change & improvement
leader
O2C Value Stream
S2P= Source to Pay; R2R=Record to Report; GBS=Global Business Services; GPE= Global Process Expert; GAFA= Global Accounting & Fixed Assets, E2E=End to end
N-1
N-2 Customer Experience
leader
10
Technology enablement
Organization set-up: • Focus on End-to-End process view • Global accountable value streams: Source-to-Pay, Record-to-Report
and Order-to-Cash • Partners such as Genpact are fully aligned to, and managed by GBS • Well defined entry point for internal customers + vendors • Continuous improvement support
Key take aways…
Benefits
• End-to-End process view and accountability allows to drive process optimization more efficiently
• Enhances accountability and allows to drive through metrics
• Reinforces collaboraion spirit and alignment
• Allows to drive transformation & operational excellence
Learnings
• Communication and early alignment at all levels
• End-to-End process view and performance management to avoid silo thinking
• Change Management
Questions? 12
Disclaimer and safe harbour
Forward-looking statements:
This presentation contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this presentation and expressly disclaims any duty to update any information contained in this presentation, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.
13
Thanks!
top related